While noting the considerable amount of time that has passed since anti-VEGF therapy became available for exudative (wet) age-related macular degeneration (AMD), Sunir Garg, MD, reflects upon the current knowns and unknowns regarding this frequently disabling disorder. Figuring among the top knowns are, first, the importance of early detection, a central factor in improving patient outcomes. This is facilitated both in terms of clinical encounters and at-home testing with devices such as the Amsler grid and a forthcoming home-based version of optical coherence tomography (OCT).
Second of these recognitions is the crucial role of continuous treatment, vital in preventing extended gaps in therapy and avoiding the perils of undertreatment, which threaten to always undermine therapeutic gains.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Treatment of Exudative (Wet) Age-Related Macular Degeneration (AMD): The Knowns and the Unknowns - Medscape - May 11, 2022.